Roche Group of Companies
Roche Diagnostics GmbH
In May 2001, Innogenetics and Roche Diagnostics entered into an exclusive licensing and collaboration agreement to develop and market a new range of rapid molecular microbiology tests combining Innogenetics’ Spacer Probe Technology and Roche Diagnostics’ PCR-based analytical platforms. Roche Diagnostics acquired a worldwide exclusive license from Innogenetics for the exploitation of the Spacer Probe patents in the field of bacteriology. Under the terms of the agreement, Roche Diagnostics paid Innogenetics an up-front amount of €10 million. Full R&D funding, substantial development milestone payments, as well as royalty payments on sales are additional financial components of the deal.
In December 2004, Innogenetics reached a milestone in development of rapid molecular microbiology testing and earned a €5 million milestone payment from Roche Diagnostics. In January 2006, Roche announced the commercial launch, initially in Europe, of SeptiFast®, a test which can rapidly detect both bacterial and fungal infections directly from a blood sample, and will be useful for the diagnosis and treatment of sepsis.
Roche Molecular Systems, Inc.
In December 2003, Innogenetics and Roche Molecular Systems entered into a new licensing agreement. Under its terms, Innogenetics granted Roche Molecular Systems a worldwide non-exclusive license to Innogenetics’ intellectual property for HCV genotyping. Roche Molecular Systems, in turn, paid Innogenetics an up-front license fee of €5 million combined with future royalty payments on genotyping product sales of Roche Molecular Systems or its affiliates.
F. Hoffman-La Roche Ltd.
In October 2005, Innogenetics signed an agreement by which F. Hoffmann-La Roche granted Innogenetics a full, worldwide license for the use of its patented polymerase chain reaction (PCR) technology in the development and commercialization of Innogenetics’ molecular diagnostic products. This agreement will allow Innogenetics to offer its customers the complete set of PCR reagents and processes to carry out PCR-based nucleic amplification for the diagnostic tests, so that its customers will not have to obtain a separate license from F. Hoffmann-La Roche for this purpose. This broad PCR license replaces a former product-specific licensing agreement.